A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)

Trial Profile

A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The "DURGA" Trial)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Viagenpumatucel-L (Primary) ; Nivolumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DURGA
  • Sponsors Heat Biologics
  • Most Recent Events

    • 28 Mar 2018 According to a Heat Biologics media release, positive interim data will be presented at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) March 16, 2018.
    • 28 Feb 2018 According to a Heat Biologics media release, interim results of this study are presented at the 2018 Keystone Symposia Conference, Immunological Memory: Innate, Adaptive and Beyond (X1)
    • 28 Feb 2018 Acording to a Heat Biologics media release, the interim results will be presented today at an analyst event.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top